Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin

Neuroendocrine (NE) differentiation may be related to the growth and progression of prostate cancer, especially androgen‐insensitive tumors. Recently the over‐expression of a new anti‐apoptosis protein, survivin, has attracted attention for its potential implication in many human cancers. The fact that NE cells in prostate are bcl‐2 negative prompted us to investigate if the prostatic NE cells over‐express survivin.

[1]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[2]  T. Kwast,et al.  Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation , 2000 .

[3]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[4]  A. Cesinaro,et al.  Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. , 1999, The Journal of investigative dermatology.

[5]  R. Weiss,et al.  Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, The New England journal of medicine.

[6]  Haojie Huang,et al.  Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer , 1999, Genes, chromosomes & cancer.

[7]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[8]  G. Sirugo,et al.  Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting* , 1998, The Journal of Biological Chemistry.

[9]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[10]  D. Vaux,et al.  Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. , 1998, Trends in biochemical sciences.

[11]  J C Reed,et al.  A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases* , 1998, The Journal of Biological Chemistry.

[12]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[13]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[14]  G. Pruneri,et al.  Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy , 1998, The Prostate.

[15]  C. Thompson,et al.  Human IAP-Like Protein Regulates Programmed Cell Death Downstream of Bcl-xL and Cytochrome c , 1998, Molecular and Cellular Biology.

[16]  F. Smedts,et al.  Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate. , 1997, The American journal of pathology.

[17]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[18]  L. McWilliam,et al.  Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.

[19]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[20]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[21]  F. Mostofi,et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.

[22]  F. Hamdy,et al.  bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. , 1996, British Journal of Cancer.

[23]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic malignancy , 1996, Cancer.

[24]  A. Partin,et al.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.

[25]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[26]  H. Moch,et al.  Prognostic significance of Bcl-2 in clinically localized prostate cancer. , 1996, The American journal of pathology.

[27]  T. H. van der Kwast,et al.  The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.

[28]  C. Heyns,et al.  Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? , 1995, British journal of urology.

[29]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[30]  R. Cohen,et al.  BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. , 1994, Archives of pathology & laboratory medicine.

[31]  V. Reuter,et al.  Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.

[32]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .

[33]  P. Scardino,et al.  Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.

[34]  L. Grimelius,et al.  The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". , 1989, Pathology, research and practice.

[35]  D. Horsfall,et al.  Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma , 1988, The Prostate.

[36]  L. Grimelius,et al.  Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. , 1987, Pathology, research and practice.

[37]  D. Evans,et al.  Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment? , 1986, Journal of clinical pathology.

[38]  T. H. van der Kwast,et al.  Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. , 2000, Cancer research.

[39]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[40]  H. Bonkhoff,et al.  Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections , 1999, Virchows Archiv.

[41]  M. Iwamura,et al.  Receptors for BPH growth factors are located in some neuroendocrine cells , 1998, The Prostate. Supplement.

[42]  P. di Sant'Agnese,et al.  Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.

[43]  F. Smedts,et al.  Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives , 1998, The Prostate. Supplement.

[44]  J. Diebold,et al.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.

[45]  M. Astill,et al.  Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients , 1998, Journal of clinical laboratory analysis.

[46]  M. Stridsberg,et al.  Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.

[47]  M. Raica,et al.  Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate. , 1996, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[48]  R. Cohen,et al.  Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer , 1995, Pathology.

[49]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma. , 1992, Human pathology.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.